Brief: NewAmsterdam Announces Positive Results From ROSE2, Phase 2 Trial

NewAmsterdam Pharma

17/01/2023 13:41

Jan 17 (Reuters) - NewAmsterdam Pharma Company NV
 NAMS.O :
    * NEWAMSTERDAM ANNOUNCES POSITIVE RESULTS FROM ROSE2, PHASE
2
TRIAL EVALUATING OBICETRAPIB IN COMBINATION WITH EZETIMIBE AS AN
ADJUNCT TO HIGH-INTENSITY STATIN THERAPY
    * NEWAMSTERDAM PHARMA COMPANY NV - ACHIEVED PRIMARY ENDPOINT
WITH
STATISTICALLY SIGNIFICANT REDUCTION IN LDL-C
    * NEWAMSTERDAM PHARMA COMPANY NV - COMBINATION OF
OBICETRAPIB AND
EZETIMIBE WAS OBSERVED TO BE WELL-TOLERATED
    * NEWAMSTERDAM PHARMA COMPANY NV - DATA SUPPORT ADVANCEMENT
OF
FIXED-DOSE COMBINATION INTO BIOEQUIVALENCE AND PHASE 3 SAFETY
AND EFFICACY TRIALS

Source text for Eikon:  ID:nGNX6jnhYj 
Further company coverage:  NAMS.O